Market access consulting and commercial strategy
At Sensa, our market access consulting services are built around one goal: helping your innovation reach the patients who need it – as quickly and profitably as possible.
Clinical trial design for payers | Payer landscape assessment | IRA & pricing architecture | HTA & JCA intelligence | Value proposition development | Competitive access intelligence | Value dossier & HTA submissions | Payer negotiation strategy | Integrated launch planning | Formulary positioning & GTN | Patient services & hub strategy | Commercial model & field access | Real-world evidence programs | Formulary defense strategy | Lifecycle & portfolio strategy | Outcomes contract monitoring | Access gap analysis
Clinical trial design for payers | Payer landscape assessment | IRA & pricing architecture | HTA & JCA intelligence | Value proposition development | Competitive access intelligence | Value dossier & HTA submissions | Payer negotiation strategy | Integrated launch planning | Formulary positioning & GTN | Patient services & hub strategy | Commercial model & field access | Real-world evidence programs | Formulary defense strategy | Lifecycle & portfolio strategy | Outcomes contract monitoring | Access gap analysis
Our Services
Our pricing, commercialization and market access consultancy is not a one-size-fits-all practice. Every engagement is shaped around your product’s unique clinical profile, the markets you’re targeting and the commercial outcomes you need to achieve.
As a specialist in commercialization and market access in pharma, we bring a rare combination of strategic depth and operational experience. We understand pharmaceutical pricing strategy from the inside – because our team has set it, defended it and renegotiated it at some of the world’s leading pharmaceutical and biotech companies.
PRE-LAUNCH
Before you file, you are already making your access decisions. Successful market access begins long before launch day. We engage in pre-launch not to prepare for access, but to shape it – working alongside clinical, medical affairs, and commercial teams before protocols are locked and evidence windows close.
Evidence strategy & HEOR
Clinical trial design for payers – endpoints, comparators, PROs that work for both FDA and HTA.
Payer landscape assessment
Mapping who controls access, what they value, and how they will respond to your asset.
IRA & pricing architecture
IRA-aware pricing strategy, indication sequencing, and global launch sequencing.
HTA & JCA intelligence
NICE, AMNOG, HAS, CADTH, and EU Joint Clinical Assessment evidence alignment.
Value proposition development
Testing the value story for payers, prescribers, and patients before it is needed in a negotiation.
Competitive access intelligence
Monitoring competitor payer strategies to sharpen your own access positioning.
LAUNCH
Approval opens a window. Access determines how wide it opens. We build integrated launch plans that align payer strategy, commercial execution, and patient services into a single coherent system.
Value dossier & HTA submissions
The evidence package that underpins every payer conversation and national submission.
Payer negotiation strategy
Scenario planning, deal structure design, and outcomes-based contract architecture.
Integrated launch planning
Access, medical, and commercial fused into one coordinated launch engine.
Formulary positioning & GTN
Contracting strategy and gross-to-net modeling that links access to financial outcomes.
Patient services & hub strategy
Support programs that drive adherence and capture the outcomes your next contract depends on.
Commercial model & field access
Go-to-market design, field access team strategy, and pull-through execution.
POST-LAUNCH
Access at launch does not secure long-term performance. Post-launch is not maintenance – it is where commercial viability is actually determined. We build the real-world evidence programs and analytics infrastructure that keep products competitive as the market evolves.
Real-world evidence programs
RWE strategies that sustain formulary position and power outcomes-based contract renewals.
Formulary defense strategy
Proactive strategy against competitive entry, biosimilar launch, and payer cost-containment.
Lifecycle & portfolio strategy
Indication expansion, LOE planning, international market entry, and portfolio prioritization.
Outcomes contract monitoring
Data governance and measurement infrastructure that makes risk-sharing contracts actually function.
AI-powered outcomes analytics
Machine learning applied to real-world data to surface evidence that changes the next payer conversation.
Access gap analysis
Identifying where patients who should be accessing therapy are not – and designing interventions.
The strategy is only as strong as the organization built to execute it
The most common failure mode in pharma commercialization is not a weak strategy. It is a strong strategy that four functions execute four different ways. We align commercial, access, medical affairs, HEOR, and patient services around a single integrated plan – with shared evidence, shared messaging, and shared accountability.
Cross-functional launch governance
Decision frameworks and RACI structures that keep access, medical, and commercial aligned under launch pressure – not just at planning.
Shared evidence & value narrative
One evidence base and value story that every function draws from consistently – from medical information to field access to brand.
Integrated planning processes
Brand, access, and evidence planning designed as one process – not parallel workstreams that attempt to reconcile at the last moment.
Launch readiness assessment
A structured cross-functional audit identifying misalignments, evidence gaps, and organizational risks before they surface at the worst moment.
Capability building & team design
Organizational design, role definition, and capability development for commercial and access functions at every stage of company maturity.
Performance & accountability systems
Shared KPIs connecting access metrics, commercial performance, and evidence milestones in a single view of launch health.
Our Services
Our market access consultancy is not a one-size-fits-all practice. Every engagement is shaped around your product’s unique clinical profile, the markets you’re targeting and the commercial outcomes you need to achieve.
As a specialist in market access in pharma, we bring a rare combination of strategic depth and operational experience. We understand pharmaceutical pricing strategy from the inside – because our team has set it, defended it and renegotiated it at some of the world’s leading pharmaceutical and biotech companies.
PRE-LAUNCH
Successful market access begins long before launch day. Our pre-launch services establish the commercial, pricing and access foundations that determine reimbursement success.
Value Assessment
Building the clinical and economic evidence base that payers and HTA bodies require.
Landscape Assessment
Mapping the competitive environment, treatment pathways and payer priorities before you enter.
Pricing & Market Access Strategy
Defining the optimal price corridor and access pathway for your product across target markets.
Due Diligence & Business Development
Supporting licensing, acquisition and partnership decisions with rigorous commercial evaluation.
LAUNCH
Our launch-phase market access strategy services translate pre-launch planning into real-world commercial execution across pricing, contracting and stakeholder engagement.
Global Pricing
Both strategic and operational. Setting and managing international reference pricing, net pricing and list price architecture.
Contracting Strategies
Structuring risk-sharing, outcomes-based and managed entry agreements that maximise access.
Value Proposition Development
Articulating your product’s value in language that resonates with payers, prescribers and patients.
Negotiation Strategies
Preparing your commercial team for HTA and payer negotiations with evidence-based tactics.
Stakeholder Mapping
Identifying and prioritising the decision-makers who matter most in each market.
Commercialisation Planning
Coordinating pricing, access and sales strategy into a unified commercialisation strategy for pharma and biotech.
POST-LAUNCH
Market access isn’t won at launch – it’s protected and expanded through strategic post-launch management.
Indication Expansion
Building the commercial and access case for new indications or patient populations.
Commercial Defence Strategies
Protecting market share against competitive entry and payer-driven price erosion.
Loss-of-Exclusivity (LoE) Defence
Planning ahead for patent expiry with pricing, brand and contracting strategies.
Cross-Portfolio Value Strategy
Maximising the cumulative value of your asset portfolio across markets and indications.
Policy & Training
Upskilling internal teams and supporting policy engagement in key markets, including the US.
About Us
We work across every stage of the commercial lifecycle, from early-stage value assessment through to post-launch defence, offering bespoke market access, pricing and commercialization strategies tailored to your product, your markets and your payer landscape.
Our engagements span pharma, biotech consulting and life science VC clients globally.